CAS |
No.75507-68-5 |
中文名称 |
氟吡啶马来酸 |
英文名称 |
Flupirtine |
别名 |
Katadolon;Flupirtinemaleate |
分子式 |
C19H21FN4O6 |
分子量 |
420.39 |
溶解性 |
Soluble in DMSO |
纯度 |
≥99% |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
运输条件 |
冷藏运输 |
EC |
EINECS 278-225-0 |
MDL |
MFCD00941415 |
SMILES |
O=C(NC1=CC=C(N=C1N)NCC2=CC=C(C=C2)F)OCC.O=C(/C=C\C(O)=O)O |
靶点 |
Potassium Channel;NMDAR |
通路 |
Membrane Transporter&Ion Channel;Neuronal Signaling |
背景说明 |
是神经元钾通道开放剂,同时具有NMDA受体拮抗剂特性。 |
生物活性 |
Flupirtine Maleate is a brain penetrant, and orally bioavailable, non-opioid and centrally acting analgesic agent. Flupirtine Maleate is an indirect N-methyl-D-aspartate receptor (NMDAR) antagonist. Neuroprotective properties[1][2]. |
In Vitro |
Flupirtine (0.1, 1, and 10 mM; 24 hours) significantly reduces the growth and viability of U373 malignant glioma cells with the GI50 of 0.47 mM.Flupirtine has neuroprotective effect of on U373 MG cells[3].Flupirtine Maleate is active at the KCNQ and GABAA channels in the range of 10-30 μM[4]. |
In Vivo |
Flupirtine (5 and 10 mg/kg) induces acute neuroprotection, reduces motor coordination impairment and ameliorates recombinant tissue plasminogen activator (rtPA)-induced toxicity[2]. |
数据来源文献 |
[1]. Jan D rr,et al. Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial. Front Neurol. 2018 Oct 9;9:842. [2]. Hanna M Jaeger, et al. The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis. Oncotarget. 2015 Jun 10;6(16):14033-44. [3]. Elango Panchanathan,Effect of flupirtine on the growth and viability of U373 malignant glioma cells.Cancer Biol Med. 2013 Sep;10(3):142-7. [4]. Martin J Gunthorpe,et al. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.Epilepsia. 2012 Mar;53(3):412-24. |
规格 |
5mg 10mg 50mg 100mg 500mg |
单位 |
瓶 |